OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
10. April 2024 12:00 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer Nantes, France – April 10, 2024 – 6:00 pm...
Informations relatives au nombre total de droits de vote et d’actions composant le capital
03. April 2024 12:00 ET
|
OSE Immunotherapeutics
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 avril 2024– En application de l’article L. 233-8 II du Code de commerce et de l’article...
OSE Immunotherapeutics annonce une publication sur CLEC-1, point de contrôle immunitaire innovant, dans la revue à Comité de lecture Journal of Immunology
02. April 2024 01:30 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics annonce une publication sur CLEC-1, point de contrôle immunitaire innovant, dans la revue à Comité de lecture Journal of Immunology Nantes, France, le 2 avril 2024, 7 heures...
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
02. April 2024 01:30 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA...
OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement
27. März 2024 13:00 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement Principaux éléments financiers Position de trésorerie de 18,7 millions...
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
27. März 2024 13:00 ET
|
OSE Immunotherapeutics
Financial highlights €18.7 million available cash as of December 31st, 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February...
OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer
13. Juli 2022 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, July 13, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer,...
OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting
23. Juni 2022 12:52 ET
|
OSE Immunotherapeutics
NANTES, France, June 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General...
OSE Immunotherapeutics Announces Collaboration with Microsoft
16. Juni 2022 01:30 ET
|
OSE Immunotherapeutics
OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech event.This collaboration will give OSE the opportunity to further...
OSE Immunotherapeutics Appoints its International Scientific Advisory Board
09. Juni 2022 12:00 ET
|
OSE Immunotherapeutics
The Scientific Advisory Board (SAB) combines the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy.The...